There are 2867 resources available
255P - Challenges to assess bone metastases in Blinded Independent Central Review (BICR) of breast cancer trials using RECIST 1.1
Presenter: Sylvain Bodard
Session: Poster session 02
256P - Difference of immunological status and response to immune checkpoint inhibitor between recurrent and de novo stage IV HER2-negative breast cancer in NEWBEAT trial (WJOG9917BTR)
Presenter: Yukinori Ozaki
Session: Poster session 02
257P - Efficacy of pembrolizumab in pre-treated breast cancer harboring high mutational load 140-290 – results from the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 02
258P - Immune checkpoint inhibitors addition to chemotherapy in older patients with metastatic triple-negative breast cancer: A systematic review and meta-analysis
Presenter: Martina Pagliuca
Session: Poster session 02
259P - Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from three phase III studies
Presenter: Peter Kaufman
Session: Poster session 02
260P - Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial
Presenter: Nicolas Epaillard
Session: Poster session 02
261P - Liquid biopsy–based biomarkers for the characterization of hormone receptor-positive (HR+) HER2-Low metastatic breast cancer (mBC)
Presenter: Lucia Bortot
Session: Poster session 02
262P - Niraparib plus aromatase inhibitors (AI) for germinal mutated BRCA1/2 (gBRCAm) or homologous recombination-deficient (HRd), hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): LUZERN interim analysis
Presenter: Isabel Pimentel
Session: Poster session 02
263P - Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)
Presenter: Adela Rodriguez Hernandez
Session: Poster session 02
264P - Increased membrane HER3 expression in brain metastases compared to primary tumors in breast cancer
Presenter: Shota Kusuhara
Session: Poster session 02